An international trial led by University of Pittsburgh scientists reported that an optogenetic gene therapy with light-projecting goggles was safe and improved visual function in selected patients with advanced retinitis pigmentosa, reinforcing a pathway for treating blindness by restoring light responsiveness. In uveitis, a UK randomized trial reported that adalimumab reduced treatment failure in non-infectious uveitis and extended benefit into patients excluded under NHS guidance, suggesting current routing rules may be too restrictive for many. In drug delivery and sensing, new research mapped how graphene contact lenses could combine sensing and drug delivery, though it flagged toxicology, manufacturing, and regulatory hurdles as remaining constraints for clinical translation. These developments collectively strengthen the case for ophthalmic innovation spanning cell-based light control, immunomodulatory biologics, and next-generation ocular platforms.